4SCAR‐GD2‐modified T‐cell therapy in neuroblastoma with MYCN amplification: A case report with over 4‐year follow‐up data
Abstract Introduction Neuroblastoma (NB) is the most common extracranial solid tumor among children. The 5‐year event‐free survival rate for high‐risk (HR) NB is still poor, especially for patients with advanced NB with MYCN gene amplification. Chimeric antigen receptor T (CAR‐T) cell therapy is a n...
Saved in:
Main Authors: | Xiao Xu (Author), Wen Zhao (Author), Zhixia Yue (Author), Maoquan Qin (Author), Mei Jin (Author), Lung‐Ji Chang (Author), Xiaoli Ma (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The potential molecularly therapy target to MYCN‐amplificated neuroblastoma
by: Susu Jiang, et al.
Published: (2023) -
Effects of preoperative chemotherapy on neuroblastoma with MYCN amplification: a surgeon's perspective
by: Chanhon Chui
Published: (2020) -
Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy
by: Xian-Ying Lu, et al.
Published: (2022) -
Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
by: Eunjin Lee, et al.
Published: (2020) -
Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and <it>MYCN </it>amplification status
by: Wei Jun S, et al.
Published: (2011)